Quarterly ResultMay 6, 2026, 04:19 PM
BillionToOne Q1 Revenue $108.4M, Raises 2026 Guidance to $450M-$465M
AI Summary
BillionToOne, Inc. reported strong financial results for the first quarter ended March 31, 2026, with total revenue increasing 84% year-over-year to $108.4 million and achieving a net income of $18.0 million. The company also raised its full-year 2026 revenue guidance to a range of $450 million to $465 million, reflecting 48% to 52% growth over 2025. Additionally, BillionToOne launched Unity ConfirmTM, a new non-invasive prenatal confirmation assay.
Key Highlights
- Total revenue increased 84% to $108.4 million in Q1 2026 from $59.0 million in Q1 2025.
- Net income was $18.0 million ($0.34 diluted EPS) in Q1 2026, compared to a net loss of $4.0 million in Q1 2025.
- Prenatal clinical testing revenue grew 72% to $96.5 million in Q1 2026.
- Oncology clinical testing revenue surged 392% to $10.7 million in Q1 2026.
- Gross profit margin improved to 73% in Q1 2026 from 64% in Q1 2025.
- Raised full-year 2026 revenue guidance to $450 million-$465 million, up from $430 million-$445 million.
- Launched Unity ConfirmTM, a new circulating fetal cell-based non-invasive confirmation assay.